DXCM [NASD]
DexCom, Inc.
IndexNDX, S&P 500 P/E144.91 EPS (ttm)0.80 Insider Own0.10% Shs Outstand386.40M Perf Week-4.37%
Market Cap45.01B Forward P/E80.05 EPS next Y1.45 Insider Trans-33.54% Shs Float384.65M Perf Month2.90%
Income341.20M PEG4.74 EPS next Q0.15 Inst Own98.80% Short Float / Ratio3.27% / 5.05 Perf Quarter2.10%
Sales2.91B P/S15.47 EPS this Y57.80% Inst Trans-0.35% Short Interest12.58M Perf Half Y41.61%
Book/sh5.52 P/B21.03 EPS next Y40.10% ROA6.60% Target Price132.74 Perf Year-5.37%
Cash/sh6.33 P/C18.33 EPS next 5Y30.60% ROE16.20% 52W Range66.89 - 134.76 Perf YTD0.48%
Dividend- P/FCF147.73 EPS past 5Y37.80% ROI8.20% 52W High-15.57% Beta1.16
Dividend %- Quick Ratio1.80 Sales past 5Y32.30% Gross Margin65.20% 52W Low70.10% ATR3.93
Employees7500 Current Ratio2.00 Sales Q/Q16.80% Oper. Margin13.40% RSI (14)49.72 Volatility2.75% 3.21%
OptionableYes Debt/Eq0.95 EPS Q/Q15.90% Profit Margin11.70% Rel Volume0.38 Prev Close116.07
ShortableYes LT Debt/Eq0.59 EarningsFeb 09 AMC Payout0.00% Avg Volume2.49M Price113.79
Recom1.70 SMA20-0.51% SMA501.76% SMA20014.31% Volume769,809 Change-1.97%
Jan-26-23Initiated Wolfe Research Outperform $121
Oct-18-22Initiated Barclays Equal Weight $103
Oct-12-22Initiated Jefferies Buy $125
Jul-15-22Initiated Bernstein Outperform $105
Mar-02-22Resumed BofA Securities Buy $500
Feb-03-22Upgrade BTIG Research Neutral → Buy $535
Jan-19-22Upgrade Wells Fargo Equal Weight → Overweight $575
Jan-07-22Upgrade Guggenheim Neutral → Buy $580
Oct-18-21Downgrade Guggenheim Buy → Neutral
Jul-21-21Resumed Cowen Outperform $540 → $525
Show Previous Ratings
Mar-25-23 05:41AM
Mar-24-23 12:10PM
11:59AM
06:59AM
Mar-23-23 09:53AM
06:15PM Loading…
Mar-21-23 06:15PM
06:00AM
Mar-20-23 09:00AM
02:15AM
Mar-18-23 06:29PM
Mar-16-23 11:14AM
Mar-15-23 06:15PM
Mar-13-23 07:30AM
Mar-09-23 06:15PM
09:53AM
08:00AM Loading…
08:00AM
Mar-08-23 10:19PM
Mar-07-23 04:59AM
Mar-06-23 04:04PM
10:05AM
Mar-03-23 06:15PM
02:38PM
08:20AM
Mar-02-23 04:04PM
05:05AM
Feb-28-23 04:56PM
05:52AM
05:00AM
Feb-24-23 09:45AM
09:37AM
09:00AM Loading…
Feb-23-23 09:00AM
Feb-22-23 04:04PM
12:00AM
Feb-21-23 09:01PM
06:45AM
Feb-20-23 09:00AM
05:21AM
Feb-19-23 09:45AM
08:25AM
Feb-18-23 09:04AM
Feb-17-23 12:37AM
Feb-13-23 03:02PM
08:53AM
08:30AM
08:30AM
Feb-11-23 07:35AM
Feb-10-23 04:59PM
04:04PM
08:52AM
Feb-09-23 11:34PM
09:30PM
05:15PM
04:13PM
04:03PM
Feb-07-23 10:05AM
Feb-06-23 09:42AM
Feb-03-23 09:37AM
Feb-02-23 06:15PM
Jan-27-23 06:15PM
Jan-25-23 11:30AM
06:39AM
Jan-24-23 09:00AM
Jan-20-23 06:15PM
07:00AM
05:10AM
Jan-17-23 06:00AM
Jan-13-23 10:09AM
Jan-12-23 06:15PM
Jan-11-23 03:41PM
10:30AM
Jan-10-23 12:47PM
05:50AM
Jan-09-23 09:00AM
08:00AM
08:00AM
Jan-06-23 08:00AM
03:43AM
Jan-05-23 11:57AM
Jan-03-23 09:00AM
Dec-30-22 06:00PM
10:35AM
Dec-28-22 06:15PM
10:37AM
Dec-22-22 06:00PM
Dec-20-22 09:53AM
Dec-19-22 09:49AM
Dec-16-22 06:00PM
Dec-15-22 09:45AM
Dec-14-22 10:03AM
Dec-12-22 08:00AM
Dec-09-22 08:30AM
Dec-08-22 09:50AM
08:45AM
Dec-06-22 12:35PM
Dec-05-22 08:20AM
07:13AM
Dec-02-22 05:08PM
Dec-01-22 10:15AM
10:07AM
05:23AM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pacelli Steven RobertEVP Managing Director Dexcom VMar 23Sale116.405,442633,449138,129Mar 27 05:08 PM
Dolan Matthew VincentSVP Corporate Strategy-DevelopMar 16Sale115.002,303264,84533,569Mar 17 04:14 PM
Stern SadieEVP Chief Human Resources OffiMar 14Sale111.8639343,96183,645Mar 15 04:03 PM
Dolan Matthew VincentSVP Corporate Strategy-DevelopMar 13Sale106.276,229661,95635,872Mar 14 04:46 PM
Flynn Paul REVP Global RevenueMar 13Sale106.272,782295,64354,893Mar 14 04:46 PM
Regan Barry J.EVP OperationsMar 13Sale106.272,010213,60370,472Mar 14 04:46 PM
Leach Jacob StevenEVP Chief Technology OfficerMar 06Sale114.7418,1442,081,822281,089Mar 06 08:05 PM
Dolan Matthew VincentSVP Corporate Strategy-DevelopMar 06Sale114.4022625,85426,536Mar 06 08:04 PM
SAYER KEVIN RPresident CEO and Chairman ofMar 01Sale109.9438,4644,228,611331,337Mar 02 05:16 PM
Pacelli Steven RobertEVP Managing Director Dexcom VFeb 23Sale111.6441245,996136,464Feb 23 06:34 PM
Sylvain Jereme MEVP Chief Financial OfficerFeb 22Sale114.542,400274,89664,837Feb 22 06:08 PM
SAYER KEVIN RPresident CEO and Chairman ofJan 30Sale106.1556,8446,034,123369,801Jan 31 04:07 PM
Regan Barry J.EVP OperationsJan 30Sale106.122,213234,84459,386Jan 31 04:07 PM
Pacelli Steven RobertEVP Managing Director Dexcom VJan 23Sale107.8641244,438136,876Jan 24 04:16 PM
SAYER KEVIN RPresident CEO and Chairman ofJan 20Sale105.7545,6074,822,872426,645Jan 24 04:17 PM
Pacelli Steven RobertEVP Managing Director Dexcom VDec 23Sale112.5741246,379137,288Dec 27 04:29 PM
Flynn Paul REVP Global RevenueDec 08Sale123.508,9881,110,01855,744Dec 08 06:07 PM
Sylvain Jereme MEVP Chief Financial OfficerNov 21Sale112.622,400270,28867,237Nov 22 06:25 PM
Dolan Matthew VincentSVP Corporate Strategy-DevelopSep 01Sale81.63540826,536Sep 06 09:33 AM
Pacelli Steven RobertEVP Managing Director Dexcom VAug 23Sale84.211,00084,210137,700Aug 24 05:25 PM
Pacelli Steven RobertEVP Managing Director Dexcom VJul 25Sale83.071,00083,070138,700Jul 25 06:00 PM
Pacelli Steven RobertEVP Managing Director Dexcom VJun 23Sale72.551,00072,550139,700Jun 27 04:46 PM
Sylvain Jereme MEVP Chief Financial OfficerJun 06Sale301.57600180,94217,408Jun 06 04:52 PM
Pacelli Steven RobertEVP Managing Director Dexcom VMay 24Sale296.3325074,08235,175May 25 04:44 PM
Patterson ChadEVP Global MarketingMay 09Sale342.77777266,33213,675May 10 04:11 PM
Pacelli Steven RobertManaging Dir., Dexcom VenturesApr 25Sale439.94250109,98535,425Apr 27 05:47 PM
Patterson ChadEVP, Global MarketingApr 11Sale498.75776387,03014,452Apr 13 04:43 PM
Regan Barry J.EVP Global OperationsMar 29Sale500.001,106553,00016,345Mar 30 05:49 PM